Eli Lilly & Co, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital reiterated a Buy rating on the stock and has a $1,300.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evan Seigerman has given his Buy rating due to a combination of factors tied to Eli Lilly’s growth profile and strategic execution. He views the Centessa acquisition as a smart expansion of Lilly’s neuroscience footprint, adding cleminorexton and related assets in narcolepsy and idiopathic hypersomnia, which strengthens the pipeline beyond its core obesity and metabolic successes.
He also emphasizes that Lilly is deploying capital from a position of financial strength to diversify well before major loss‑of‑exclusivity events, supporting more durable revenue streams. In his assessment, the company’s diabetes and obesity franchises, emerging neuroscience portfolio, recent Alzheimer’s approval, and a solid oncology business together underpin superior top‑ and bottom‑line growth versus peers, justifying a continued Buy recommendation.
In another report released today, TipRanks – Google also reiterated a Buy rating on the stock with a $1,042.00 price target.
LLY’s price has also changed moderately for the past six months – from $763.000 to $919.770, which is a 20.55% increase.